For noninfectious diarrhea in adults living with HIV/AIDS who are on ART*

What is Mytesi?

Mytesi (crofelemer) is the only antidiarrheal studied in and FDA-approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS.*

  • Treats diarrhea differently by normalizing the flow of water in the gastrointestinal tract (GI)
  • No clinically relevant drug-drug interactions
  • No effect on viral load or CD4 counts
  • In clinical trials, adverse events with Mytesi were comparable to or lower than those with placebo
  • Mytesi is extracted and purified from the bark sap of the Croton lechleri tree sustainably harvested in the Amazon rainforest
  • *Indication

    MYTESI™ is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information

Who could benefit from Mytesi?

Mytesi is an antidiarrheal that has been specifically studied in and FDA-approved for adults living with HIV/AIDS on ART. Mytesi provides symptomatic relief of noninfectious diarrhea in HIV+ patients.

If you suffer with diarrhea, you want relief. You want a treatment option with a low rate of side effects, no effect on viral load or CD4 counts, and no clinically relevant drug-drug interactions. You want Mytesi.

 

What is noninfectious diarrhea?

Noninfectious diarrhea is not caused by bacteria or other infectious agents.

In people living with HIV/AIDS, noninfectious diarrhea may be a side effect of ART or it may be due to HIV enteropathy. HIV enteropathy is chronic diarrhea thought to be due to the effects of HIV on the lining of the intestine.

How to take Mytesi

  • Take one 125mg tablet, twice a day, with or without food
  • Since Mytesi has no clinically relevant drug-drug interactions, it won't interfere with ART

1. Orange Book, www.accessdata.fda.gov/scripts/cder/ob/, accessed October 2016

For product information, adverse event reports, and product complaint reports, please contact: 
Napo Pharmaceuticals     
email: napopharma@missionpharmacal.com        
phone: (844) 722-8256

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

©2016 Napo Pharmaceuticals Inc. All rights reserved.

350a-g-1

How to take Mytesi

  • Take one 125mg tablet, twice a day, with or without food
  • Since Mytesi has no clinically relevant drug-drug interactions, it won't interfere with ART
  • *Indication

    MYTESI™ is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information

What is Mytesi?

Mytesi (crofelemer) is the only antidiarrheal studied in and FDA-approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS.*

  • Treats diarrhea differently by normalizing the flow of water in the gastrointestinal tract (GI)
  • No clinically relevant drug-drug interactions
  • No effect on viral load or CD4 counts
  • In clinical trials, adverse events with Mytesi were comparable to or lower than those with placebo
  • Mytesi is extracted and purified from the bark sap of the Croton lechleri tree sustainably harvested in the Amazon rainforest

 

How to take Mytesi

  • Take one 125mg tablet, twice a day, with or without food
  • Since Mytesi has no clinically relevant drug-drug interactions, it won't interfere with ART

Who could benefit from Mytesi?

  • Mytesi is an antidiarrheal that has been specifically studied in and FDA-approved for adults living with HIV/AIDS on ART. Mytesi provides symptomatic relief of noninfectious diarrhea in HIV+ patients.
  • If you suffer with diarrhea, you want relief. You want a treatment option with a low rate of side effects, no effect on viral load or CD4 counts, and no clinically relevant drug-drug interactions. You want Mytesi.

What is noninfectious diarrhea?

Noninfectious diarrhea is not caused by bacteria or other infectious agents.

In people living with HIV/AIDS, noninfectious diarrhea may be a side effect of ART or it may be due to HIV enteropathy. HIV enteropathy is chronic diarrhea thought to be due to the effects of HIV on the lining of the intestine.

 

1. Orange Book, www.accessdata.fda.gov/scripts/cder/ob/, accessed October 2016

 

  • *Indication

    MYTESI™ is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

 

©2016 Napo Pharmaceuticals Inc. All rights reserved.

350a-g-1

For product information, adverse event reports, and product complaint reports, please contact: 
Napo Pharmaceuticals     
email: napopharma@missionpharmacal.com        
phone: (844) 722-8256

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

 

©2016 Napo Pharmaceuticals Inc. All rights reserved.

350a-g-1

  • *Indication

    MYTESI™ is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information

  • *Indication

    MYTESI™ is an anti-diarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious

    diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information